A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

NCT04666168 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-hodgkin's Lymphoma

Interventions

BIOLOGICAL: Auto CAR-T
DRUG: Cyclophosphamide,Fludarabine
PROCEDURE: Leukapheresis

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.

Collaborators

[object Object]